Letters to the Editor
New drug - teriparatide
- Troels Wolthers
- Aust Prescr 2004;27:109-13
- 1 October 2004
- DOI: 10.18773/austprescr.2004.092
The Editorial Executive Committee welcomes letters, which should be less than 250 words. Before a decision to publish is made, letters which refer to a published article may be sent to the author for a response. Any letter may be sent to an expert for comment. When letters are published, they are usually accompanied in the same issue by their responses or comments. The Committee screens out discourteous, inaccurate or libellous statements. The letters are sub-edited before publication. Authors are required to declare any conflicts of interest. The Committee's decision on publication is final.
Editor, – Your recent comment on our product Fortéo (teriparatide) (Aust Prescr 2004;27:21-3) was an informative and well-rounded review, however, I would like to address a couple of points.
Your final paragraph states: 'Until more data are available teriparatide should only be prescribed for patients who have a high risk of fractures and cannot take other treatments for osteoporosis'.
In fact, the product information approved by the Therapeutic Goods Administration for the use of teriparatide states:
Fortéo is indicated for the treatment of osteoporosis in postmenopausal women and the treatment of primary osteoporosis in men when other agents are considered unsuitable and when there is a high risk of fractures.
While this may seem like a small change in wording, it is actually a significant consideration for those prescribing Fortéo.
A published paper helps to place the rat osteosarcoma issue in context. It concluded that: 'in adult humans† it is unlikely that the risk of bone neoplasia would be increased by daily treatment with PTH (1-34) for a relatively small fraction of the normal life span'.1
Medical Advisor Endocrine
Eli Lilly Australia
West Ryde, NSW
Medical Advisor Endocrine, Eli Lilly Australia West Ryde, NSW